Annals of Hematology

, Volume 94, Issue 7, pp 1149–1157 | Cite as

Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives

  • Jury L. Shevchenko
  • Alexey N. Kuznetsov
  • Tatyana I. IonovaEmail author
  • Vladimir Y. Melnichenko
  • Denis A. Fedorenko
  • Kira A. Kurbatova
  • Gary I. Gorodokin
  • Andrei A. Novik
Original Article


High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (AHSCT) is a promising approach to treatment of multiple sclerosis (MS) patients. In this paper, we present the long-term outcomes of a prospective single-center study with the analysis of the safety and efficacy of HDIT + AHSCT with reduced-intensity BEAM-like conditioning regimen in 99 MS patients: mean age—35 years old; male/female—39/60; median Expanded Disability Status Scale (EDSS) = 3.5; 43 relapsing/remitting MS, 56 progressive MS. No transplant-related deaths were observed. The mobilization and transplantation procedures were well tolerated. At 6 months post-transplant, neurological improvement or stabilization was observed in all the patients except one. Cumulative incidence of disease progression was 16.7 % at 8 years after HDIT + AHSCT. Estimated event-free survival at median follow-up of 48.9 months was 80 %: 83.3 % in relapsing/remitting MS vs 75.5 % in progressive MS. Sixty-four patients who did not progress during the first 3 years post-transplant and were monitored for more than 3 years were included in long-term outcome analysis. At the median long-term follow-up of 62 months, 47 % of patients improved by at least 0.5 points on the EDSS scale as compared to baseline and exhibited improvement during the entire period of follow-up; 45 % of patients were stable. No active, new, or enlarging lesions on magnetic resonance imaging were registered in patients without disease progression. AHSCT was accompanied by a significant improvement in patient’s quality of life. Due to the fact that patient selection was quite different to the other studies and that the information about disease activity prior in the disease course and its treatment was inhomogeneous, comparison with the results in the literature should be done with caution. Thus, the risk/benefit ratio of HDIT + AHSCT with reduced-intensity BEAM-like conditioning regimen in our population of MS patients is very favorable. The consistency of our long-term clinical and quality of life results, together with the persistence of improvement, is in favor of the efficacy and safety of this treatment approach in MS patients.


Autologous hematopoietic stem cell transplantation Clinical outcomes Multiple sclerosis Patient-reported outcomes Long-term outcomes 



We would like to acknowledge Andrei V. Kartashov (Moscow) and Ruslana V. Kruglina (Moscow) for their contribution to the study.

Conflict of interest

No financial interest/relationships with financial interest relating to the topic of this article have been declared.


  1. 1.
    Weinshenker BG (1995) The natural history of multiple sclerosis. Neurol Clin 3:119–146Google Scholar
  2. 2.
    Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, BaskervilleJ EGC (1989) The natural history of multiple sclerosis: a geographically based study. I Clinical course and disability. Brain 112:133–146CrossRefPubMedGoogle Scholar
  3. 3.
    Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H (1998) McAlpine’s multiple sclerosis, 3rd edn. Churchill Livingstone, EdinburghGoogle Scholar
  4. 4.
    Fischer JM, Bramow S, Dal Biaco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189CrossRefGoogle Scholar
  5. 5.
    Burt RK, Cohen B, Rose J et al (2005) Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62:860–864PubMedGoogle Scholar
  6. 6.
    Fassas A, Anagnostopoulos A, Kazis A et al (2000) Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 20(1):24–30CrossRefPubMedGoogle Scholar
  7. 7.
    Brenner MK (2004) Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract Res Clin Haematol 17:359–374CrossRefPubMedGoogle Scholar
  8. 8.
    Fassas A, Passweg JR, Anagnostopoulos A et al (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249:1088–1097CrossRefPubMedGoogle Scholar
  9. 9.
    Kozak T, Havrdova E, Pit’ha J et al (2000) High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 25:525–531CrossRefPubMedGoogle Scholar
  10. 10.
    Saccardi R, Mancardi GL, Solari A et al (2005) Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105:2601–2607CrossRefPubMedGoogle Scholar
  11. 11.
    Shevchenko Y, Novik A, Ionova T et al (2004) Clinical and quality of life outcomes in patients with multiple sclerosis after high-dose chemotherapy + autologous stem cell transplantation [abstract no. 1875]. Blood 104:519aCrossRefGoogle Scholar
  12. 12.
    Shevchenko Y, Novik A, Kuznetsov A et al (2008) High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 36(8):922–929CrossRefPubMedGoogle Scholar
  13. 13.
    Ni XS, Ouyang J, Zhu WH, Wang C, Chen B (2006) Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 20:485–489CrossRefPubMedGoogle Scholar
  14. 14.
    Saccardi R, Kozak T, Bocelli-Tyndall C et al (2006) Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 12:814–823CrossRefPubMedGoogle Scholar
  15. 15.
    Hamerschlak N, Rodrigues M, Moraes DA et al (2010) Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 45(2):239–248CrossRefPubMedGoogle Scholar
  16. 16.
    Rogojan C, Frederiksen JL (2009) Hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol Scand 120(6):371–382CrossRefPubMedGoogle Scholar
  17. 17.
    Shevchenko J, Kuznetsov A, Ionova T et al (2012) Autologous hematopoietic stem cell transplantation with reduced intensity conditioning in multiple sclerosis. Exp Hem 40(11):892–898CrossRefGoogle Scholar
  18. 18.
    Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231CrossRefPubMedGoogle Scholar
  19. 19.
    Hays RD, Sherbourne CD, Mazel RM. User’s manual for Medical Outcomes Study (MOS) core measures of health-related quality of life. RAND Corporation, MR-162-RC.
  20. 20.
    Snowden JA, Saccardi R, Allez M, Paediatric Diseases Working Party (PDWP) et al (2011) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47(6):770–790. doi: 10.1038/bmt.2011.185 CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Kimiskidis VK, Fassas A (2013) Stem cell-based therapies in multiple sclerosis. J Genet Syndr Gene Ther S3. doi: 10.4172/2157-7412.S3-006
  22. 22.
    Saccardi R, Freedman MS, Sormani MP et al (2012) A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 18(6):825–834CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K (2011) Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 17(2):204–213CrossRefPubMedGoogle Scholar
  24. 24.
    Atkins HL, Freedman MS (2013) Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics 10:68–76CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Burt RK, Cohen BA, Russell E et al (2003) Hematopoietic stem cell transplantation for progressive multiple sclerosis; failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102:2373–2378CrossRefPubMedGoogle Scholar
  26. 26.
    Burman J, Iacobaeus E, Svenningsson A et al (2014) Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 19. doi:10.1136/jnnp-2013-307207Google Scholar
  27. 27.
    Bowen JD, Kraft GH, Wundes A et al (2012) Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant 47(7):946–951CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Chen B, Zhou M, Ouyang J et al (2012) Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci 33(4):881–886. doi: 10.1007/s10072-011-0859-y CrossRefPubMedGoogle Scholar
  29. 29.
    Fassas A, Kimiskidis VK, Sakellari I et al (2011) Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76(12):1066–1070CrossRefPubMedGoogle Scholar
  30. 30.
    Burt RK, Marmont A, Oyama Y et al (2006) Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative transplant regimens. Arthritis Rheum 54:3750–3760CrossRefPubMedGoogle Scholar
  31. 31.
    Mancardi G, Saccardi R (2008) Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7:626–636CrossRefPubMedGoogle Scholar
  32. 32.
    Mancardi GL (2007) Present status of HSCT in MS. Mult Scler 13(2):22Google Scholar
  33. 33.
    Saiz A, Blanco Y, Carreras E et al (2004) Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology 62:282–284CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Jury L. Shevchenko
    • 1
  • Alexey N. Kuznetsov
    • 2
  • Tatyana I. Ionova
    • 3
    Email author
  • Vladimir Y. Melnichenko
    • 3
  • Denis A. Fedorenko
    • 3
  • Kira A. Kurbatova
    • 4
  • Gary I. Gorodokin
    • 5
  • Andrei A. Novik
    • 3
  1. 1.Pirogov National Medical Surgical CenterMoscowRussia
  2. 2.Department of NeurologyPirogov National Medical Surgical CenterMoscowRussia
  3. 3.Department of Hematology and Cellular TherapyPirogov National Medical Surgical CenterMoscowRussia
  4. 4.Biostatistics UnitMultinational Center for Quality of Life ResearchSt. PetersburgRussia
  5. 5.Health Outcomes DepartmentNew Jersey Centre for Quality of Life and Health Outcomes ResearchSaddle RiverUSA

Personalised recommendations